Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.
about
Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptorObesity pharmacotherapy: current perspectives and future directionsAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentNutrient-sensing mechanisms in the gut as therapeutic targets for diabetesTherapy for obesity based on gastrointestinal hormonesObesity treatment: novel peripheral targets.A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.Diminished mTOR signaling: a common mode of action for endocrine longevity factors.Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potentialCurrent and future drug targets in weight managementElimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.Appetite regulation and weight control: the role of gut hormones.Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.Oat consumption reduced intestinal fat deposition and improved health span in Caenorhabditis elegans model.Minireview: Gut peptides: targets for antiobesity drug development?Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake.Molecular neuroendocrine targets for obesity therapy.Control of Food Intake by Gastrointestinal Peptides: Mechanisms of Action and Possible Modulation in the Treatment of Obesity.Peripheral signalling involved in energy homeostasis control.Do we need anti-obesity drugs?Neuroendocrinology of obesity.Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.New molecular targets in the pathophysiology of obesity and available treatment options under investigation.Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways.Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype.Species- and dose-specific pancreatic responses and progression in single- and repeat-dose studies with GI181771X: a novel cholecystokinin 1 receptor agonist in mice, rats, and monkeys.The current state of GPCR-based drug discovery to treat metabolic disease.
P2860
Q24628602-2A0CAB4A-3498-48BF-ACC2-55BDF789462BQ26828559-316BA0F7-064B-4E35-8B98-6D772055ACDFQ26830274-A7B10D76-E21E-4C5E-AAB1-253F754F5854Q26992197-E4BD47B6-B876-4E03-A6D3-F09E9CA3AA8DQ27006777-57D05DAB-63B9-4049-AED2-051B31F6A804Q33607971-0ACF76DE-CFBB-42B3-ACF7-6B2F1E14A239Q34073933-A8552E9C-85D2-48DB-A4A6-C76D48FF644BQ34462362-166170BD-5B60-4A1E-A647-F2995BFA2CDDQ34712671-F4091600-1E39-453E-98BA-D77410C895CEQ35089784-4D4A013F-36D6-49B6-A039-BCF8FD159A7EQ35533535-3EC0ACE4-EC6C-42DE-A253-D1647A5887E0Q35825708-3A5D6DE0-70C9-4F43-8348-0A4AE49F80B4Q36017828-12D81B48-6A2C-4517-B3BA-653459A7DAD2Q36032794-E158FCCE-2F57-45E7-8FC7-322C0BDD5805Q37210769-7C12329F-74CA-4BFA-A96C-44E354686671Q37417444-06AEDCF8-F2E1-4C03-927A-F590AACDF9EAQ37569030-1F809071-A81D-424B-9824-2B715311A2E6Q37740010-B02E3005-36FF-4B12-B871-93A49F0754E9Q38061797-AAD39CE6-E811-4026-80F6-FD71C704F181Q38071006-0AD6C7F3-B880-4496-BA71-D30DD7BEFFFEQ38185643-6E1C55D4-D2F3-4567-A3B7-14AE435677E3Q38304318-0094B46B-80FA-4A36-A11A-38C495473B13Q38397535-B6107266-3EC4-43A8-A3BC-7E197E250775Q38828407-9B9A6014-A979-40F5-AE28-05A661CF5A52Q39103483-3BAA9309-1F87-45FC-9EF6-A13702F5E9E0Q39888037-EF1709C1-D307-4843-B0A5-4D135E9AE2A2Q40168206-051676B5-1897-48BB-92A1-EE42BBD10D64Q46976579-A76C127A-C74B-417C-9F7A-CE13ADF04909Q47696468-ED707D91-C874-4DAD-89AC-6FD4C40AB8A8
P2860
Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Stimulation of cholecystokinin ...... overweight or obese patients.
@en
Stimulation of cholecystokinin ...... overweight or obese patients.
@nl
type
label
Stimulation of cholecystokinin ...... overweight or obese patients.
@en
Stimulation of cholecystokinin ...... overweight or obese patients.
@nl
prefLabel
Stimulation of cholecystokinin ...... overweight or obese patients.
@en
Stimulation of cholecystokinin ...... overweight or obese patients.
@nl
P2093
P2860
P356
P1476
Stimulation of cholecystokinin ...... overweight or obese patients.
@en
P2093
Aftring RP
Greenway FL
Jacobson P
P2860
P2888
P304
P356
10.1038/SJ.CLPT.6100272
P407
P577
2007-06-27T00:00:00Z
P5875
P6179
1002106652